Notes from the Field: Cardiac Dysrhythmias After Loperamide Abuse - New York, 2008-2016
| Autor: | Maria Mercurio-Zappala, William Eggleston, Christine M. Stork, Joshua G. Schier, Jeanna M. Marraffa, Mark K. Su, Karen R. Cummings, Rachel S. Wightman |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Agonist
Gerontology Adult Male Loperamide Health (social science) Poison Control Centers Adolescent Databases Factual Epidemiology medicine.drug_class Substance-Related Disorders Health Toxicology and Mutagenesis New York Poison control 030204 cardiovascular system & hematology Euphoriant 03 medical and health sciences Young Adult 0302 clinical medicine Health Information Management medicine Humans 030212 general & internal medicine Child Depression (differential diagnoses) Aged Aged 80 and over Cardiotoxicity business.industry Arrhythmias Cardiac General Medicine Middle Aged Poison control center Opioid Anesthesia Female business medicine.drug |
| Zdroj: | MMWR. Morbidity and mortality weekly report. 65(45) |
| ISSN: | 1545-861X |
| Popis: | Loperamide is an over-the-counter antidiarrheal with opioid-receptor agonist properties. Recommended over-the-counter doses (range = 2-8 mg daily) do not produce opioid effects in the central nervous system because of poor oral bioavailability and P-glycoprotein efflux* of the medication (1); recent reports suggest that large doses (50-300 mg) of loperamide produce euphoria, central nervous system depression, and cardiotoxicity (2-4). Abuse of loperamide for its euphoric effect or for self-treatment of opioid withdrawal is increasing (5). Cases of loperamide abuse reported to the Upstate New York Poison Center and New York City Poison Control Center were analyzed for demographic, exposure, clinical, and laboratory characteristics. Cases of intentional loperamide abuse reported to the National Poison Database System (NPDS) also were analyzed for demographic, dose, formulation, and outcome information. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|